Search Results - "Pommier, Yves G."

RedundancyMiner: De-replication of redundant GO categories in microarray and proteomics analysis by Zeeberg, Barry R, Liu, Hongfang, Kahn, Ari B, Ehler, Martin, Rajapakse, Vinodh N, Bonner, Robert F, Brown, Jacob D, Brooks, Brian P, Larionov, Vladimir L, Reinhold, William, Weinstein, John N, Pommier, Yves G

“…The Gene Ontology (GO) Consortium organizes genes into hierarchical categories based on biological process, molecular function and subcellular localization…”
Get full text

Detailed DNA methylation profiles of the E-cadherin promoter in the NCI-60 cancer cells by Reinhold, William C, Reimers, Mark A, Maunakea, Alika K, Kim, Sohyoung, Lababidi, Samir, Scherf, Uwe, Shankavaram, Uma T, Ziegler, Micah S, Stewart, Claudia, Kouros-Mehr, Hosein, Cui, Hengmi, Dolginow, Douglas, Scudiero, Dominic A, Pommier, Yves G, Munroe, David J, Feinberg, Andrew P, Weinstein, John N

“…E-cadherin (E-cad) is a transmembrane adhesion glycoprotein, the expression of which is often reduced in invasive or metastatic tumors. To assess E-cad's…”
Get full text

Using drug response data to identify molecular effectors, and molecular “omic” data to identify candidate drugs in cancer by Reinhold, William C., Varma, Sudhir, Rajapakse, Vinodh N., Luna, Augustin, Sousa, Fabricio Garmus, Kohn, Kurt W., Pommier, Yves G.

“…The current convergence of molecular and pharmacological data provides unprecedented opportunities to gain insights into the relationships between the two…”
Get full text

Chk1 inhibition after replicative stress activates a double strand break response mediated by ATM and DNA-dependent protein kinase by McNeely, Samuel, Conti, Chiara, Sheikh, Tahir, Patel, Himali, Zabludoff, Sonya, Pommier, Yves G., Schwartz, Gary K., Tse, Archie

“…Checkpoint kinase 1 (Chk1) regulates cell cycle checkpoints and DNA damage repair in response to genotoxic stress. Inhibition of Chk1 is an emerging strategy…”
Get full text

Multifactorial regulation of E-cadherin expression: an integrative study by Reinhold, William C, Reimers, Mark A, Lorenzi, Philip, Ho, Jennifer, Shankavaram, Uma T, Ziegler, Micah S, Bussey, Kimberly J, Nishizuka, Satoshi, Ikediobi, Ogechi, Pommier, Yves G, Weinstein, John N

“…E-cadherin (E-cad) is an adhesion molecule associated with tumor invasion and metastasis. Its down-regulation is associated with poor prognosis for many…”
Get full text

Effects of acetylation, polymerase phosphorylation, and DNA unwinding in glucocorticoid receptor transactivation by Kim, Yuli, Sun, Yunguang, Chow, Carson, Pommier, Yves G., Simons, S. Stoney

“…Varying the concentration of selected factors alters the induction properties of steroid receptors by changing the position of the dose–response curve (or the…”
Get full text

Etoposide Metabolites Enhance DNA Topoisomerase II Cleavage near Leukemia-Associated MLL Translocation Breakpoints by Lovett, Brian D, Strumberg, Dirk, Blair, Ian A, Pang, Shaokun, Burden, Donald A, Megonigal, Maureen D, Rappaport, Eric F, Rebbeck, Timothy R, Osheroff, Neil, Pommier, Yves G, Felix, Carolyn A

“…Chromosomal breakage resulting from stabilization of DNA topoisomerase II covalent complexes by epipodophyllotoxins may play a role in the genesis of…”
Get full text

Abstract IA21: PARP trapping and Schlafen 11 to kill cancer cells by Pommier, Yves G., Murai, Junko

“…Poly(ADP-ribose) polymerase inhibitors (PARPIs) kill cancer cells by trapping PARP1 and PARP2. Talazoparib, the most potent PARP inhibitor (PARPI), exhibits…”
Get full text

Abstract B189: New class of TOP1 inhibitors selective for HR deficiencies and SLFN11 expression by Marzi, Laetitia, Pommier, Yves G.

“…To relax DNA supercoiling, topoisomerase I (TOP1) induces DNA cleavage complexes (TOP1cc). These TOP1cc can be trapped by camptothecin, leading to…”
Get full text

Abstract PL05-04: PARP trapping versus PARP catalytic inhibition and coupling with TDP1 by Pommier, Yves G., Murai, Junko

“…The five clinical PARP inhibitors (veliparib, olaparib, niraparib, rucaparib and talazoparib) are potent submicromolar competitive NAD+ inhibitors for PARP1…”
Get full text

Abstract CN05-03: Precision therapeutics with DNA-damaging agents by Pommier, Yves G., Reinhold, William C., Murai, Junko, Thomas, Anish

“…Precision therapeutics can be defined as the ability to prescribe effective (curative) therapies only to those patients who will respond, while limiting…”
Get full text

Abstract 3421: Differential potentiation of temozolomide and camptothecin by the PARP inhibitors olaparib and veliparib in relationship with their PARP-DNA trapping abilities, and lack of impact of PARP inhibitors on cisplatin activity by Pommier, Yves G., Murai, Junko

“…We recently showed that poly(ADP-ribose) polymerase (PARP) inhibitors act by a novel allosteric mechanism of action that involves the trapping of PARP-DNA…”
Get full text

RNA synthesis inhibitors alter the subnuclear distribution of DNA topoisomerase I by BUCKWALTER, C. A, LIN, A. H, TANIZAWA, A, POMMIER, Y. G, YUNG-CHI CHENG, KAUFMANN, S. H

“…The acute effect of RNA and DNA synthesis inhibitors on DNA topoisomerase (topo) I localization within cells was examined. Indirect immunofluorescence revealed…”
Get full text

Abstract LB167: Acetalax (Oxyphenisatin acetate, NSC 59687) and bisacodyl (dulcolax) cause oncosis in triple negative breast cancer by poisoning the ion exchange membrane protein TRPM4 by Mizunuma, Makito, Redon, Christophe, Saha, Liton, Takebe, Naoko, Pommier, Yves G.

“…Triple negative breast cancer (TNBC) is generally unresponsive to current therapies, and the development of new anticancer agents is needed. Oxyphenisatin…”
Get full text

Abstract CN08-04: Novel topoisomerase I inhibitors in development by Pommier, Yves G.

“…Camptothecins are effective against previously resistant tumors. Because camptothecins are presently the only class of topoisomerase I (Top1) inhibitors…”
Get full text

Abstract 4689: Stabilization of PARP-DNA complexes plays a critical role for the cytotoxic effects of the PARP inhibitors, veliparib and oliparib by Pommier, Yves G., Murai, Junko, Takeda, Shunichi

“…Poly(ADPribose) (PAR) polymerase (PARP) inhibitors are in clinical trials with alkylating agents such as temozolomide and topoisomerase I (Top1) inhibitors…”
Get full text

Abstract CN05-01: PARP inhibitors: Trapping of PARP and rational for combinations by Pommier, Yves G., Murai, Junko, Morris, Joel, Doroshow, James H.

“…Poly(ADPribose) polymerases (PARPs) are promising targets of several anticancer drugs in clinical development. We will review the genetic and biochemical…”
Get full text

Abstract C204: Potentiation of the novel topoisomerase I inhibitor indenoisoquinoline LMP-400 by the Chk1/2 inhibitor, AZD7762 by Aris, Sheena M., Pommier, Yves G.

“…Novel topoisomerase I (Top1) inhibitors are in clinical development to circumvent the drawbacks of camptothecins (1–3). Here we report molecular investigations…”
Get full text

Abstract 3620: A multiplex quantitative immunofluorescence assay for DNA damage repair in response to cytotoxic treatment by Marrero, Allison M., Lawrence, Scott M., Balasubramanian, Priya, Pommier, Yves G., Tomaszewski, Joseph E., Parchment, Ralph E., Doroshow, James H., Kinders, Robert J.

“…The use of DNA damaging agents remains one of the most common approaches to cancer therapy. The type of damage caused by the agent will determine which of the…”
Get full text

Abstract 3051: mRNA and microRNA expression profiles integrated with drug sensitivities of the NCI-60 human cancer cell lines by Liu, Hongfang, D'Andrade, Petula, Fulmer-Smentek, Stephanie, Lorenzi, Philip, Kohn, Kurt, Weinstein, John, Pommier, Yves G., Reinhold, William C.

“…We present here new NCI-60 profiling studies of mRNA and miRNA expression using the 41,000-probe Agilent Whole Human Genome Oligo Microarray and the…”
Get full text